Hurley Karen E, Chapman Paul B
Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Oncologist. 2005 Oct;10(9):739-42. doi: 10.1634/theoncologist.10-9-739.
High-dose interferon-alpha2b is a U.S. Food and Drug Administration-approved adjuvant treatment for stage III melanoma, and yet, because of its limited efficacy and well-known toxicity, it is not universally accepted by patients and oncologists. In this paper, we evaluate the benefits and risks of adjuvant high-dose interferon-alpha2b and try to provide a framework to help oncologists guide patients trying to decide whether to undergo adjuvant high-dose interferon therapy.
高剂量干扰素-α2b是美国食品药品监督管理局批准的用于III期黑色素瘤的辅助治疗药物，然而，由于其疗效有限且毒性众所周知，患者和肿瘤学家并未普遍接受。在本文中，我们评估了辅助性高剂量干扰素-α2b的益处和风险，并试图提供一个框架，以帮助肿瘤学家指导患者决定是否接受辅助性高剂量干扰素治疗。
